Dementia Discovery Fund

The Dementia Discovery Fund is a specialist therapeutic-focused venture fund dedicated entirely to dementia and neurodegeneration drug discovery and development. Backed by major pharmaceutical companies, governments, and philanthropic partners, the fund invests in early-stage therapeutic platforms targeting Alzheimer’s disease, Parkinson’s, frontotemporal dementia, and related neurodegenerative conditions. The fund has a sharply scoped thesis and meaningful capital, with typical investments ranging from low single-digit millions to multi-million dollar commitments, often as a syndicate participant or lead in seed and Series A therapeutic rounds. For healthcare AI founders, the Dementia Discovery Fund is a fit only if you are building AI applied to dementia and neurodegeneration drug discovery, target identification, biomarker discovery, clinical trial enrichment, or related therapeutic applications. Companies in digital cognitive assessment, dementia care delivery, caregiver software, or non-therapeutic dementia tools may have a narrow fit if there is a clear path to therapeutic value, but pure software or care-delivery plays will likely not match the fund’s mandate. Founders outside the dementia and neurodegeneration vertical should not pursue this fund, regardless of how compelling their broader healthcare AI thesis is; the mandate is binary. The fund’s value-add is exceptional within its scope, with deep scientific expertise, pharma syndicate access, and credibility with regulators and clinical investigators. Entry path is through the website inquiry form, Crunchbase-listed contacts, or referral from a portfolio scientific founder or pharma partner. Founders should come with deep scientific data, target rationale, and a credible IND-enabling plan; commercial-style pitches without clinical and scientific depth will not convert.